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Introduction
Soft tissue sarcomas (STS) are a biologically complex and remarkably heterogeneous group of uncommon tumors of mesenchymal origin that represent only 1% of all human malignancies (1) . These tumors have distinctive histology and a wide spectrum of clinicopathological features. More than 100 different malignant and benign soft tissue neoplasms are classified by the World Health Organization (WHO). This vastness and variety of soft tissue neoplasms makes their diagnosis and classification difficult, and undoubtedly one of the most complex areas in clinical pathology, resulting in a high rate of misdiagnosis and misclassification (2, 3) . Although assessment of pathologic subtypes or grades of an individual sarcoma is a means of predicting its clinical behavior and is important to determine therapeutic strategies, it is a frequent diagnostic dilemma; therefore, a disagreement rate of 40% exists between expert pathologists (4) . Due to difficulties to diagnose and classify soft tissue sarcomas, molecular methods such as FISH and polymerase chain reaction (PCR)-based techniques are routinely used to diagnose and classify some types of STS as alternative methods (5) . The two most important and prevalent soft tissue sarcomas in adults are liposarcomas (LPS) and synovial sarcomas (SS), representing about 17% to 25% and 10% of total cases, respectively (6, 7) .
According to histopathological diagnostic criteria, liposarcomas and synovial sarcomas can be subdivided into four and three main subtypes, respectively; each with its own specific and unique clinicopathological characteristics and behavior.
Well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoidliposarcoma (MLPS), and pleomorphic liposarcoma (PLPS) are the main subtypes of liposarcoma; mono phasic, biphasic, and poorly differentiated synovial sarcomas are the main subtypes of synovial sarcomas (8, 9) .
The morphological diversity of liposarcomas and synovial sarcomas reflects the variation in their clinicopathological behavior ranging from tumors with low risk for metastasis, such as WDLPS, to tumors with high risk for metastasis, such as the round cell (RC) variant of MLPS or PLPS, and poorly differentiated synovial sarcoma (10, 11) . Differential diagnosis is of the critical importance to diagnose and treat liposarcomas and synovial sarcomas. Differentiating liposarcomas from lipomas, synovial sarcomas from fibrosarcomas or leiomyosarcomas, and classification of these types of sarcomas are crucial to provide patients with therapeutic strategies and predict their prognosis, although LPS and SS may not have notable findings on histopathology; the result is a high rate of their misdiagnosis and misclassification.
Several studies showed the potential utility of genetic approaches to detect liposarcoma and synovial sarcoma and their classification (12) (13) (14) (15) .
Lioposarcomas and synovial sarcomas, similar to many types of soft tissue sarcomas, are associated with specific genetic alterations such as translocations and amplifications, which are helpful to diagnose individual cases (16) .
Regarding liposarcomas, MDM2 gene amplification and CHOP gene rearrangement are useful to sub classify liposarcomas, and can be utilized to differentiate certain subtypes of liposarcomas from benign lipomas (17) . Primary amplification of MDM2 is predominantly observed in WDLPS and DDLPS, but not in benign lipomas and PLP cases, making this feature a useful tool to differentiate WDLPS and DDLPS from benign lipomas and PLP (18) . MDM2 amplification is not observed in PLP cases (19) .
CHOP (DDIT3) gene rearrangement is the main feature of myxoidliposarcomas (MLPS) and is observed in nearly all cases of MLPS. A t(12;16), or t(12;22) translocation, leading to fusion of CHOP (DDIT3) located on 12q13 with TLS (FUS) on 16p11 or EWSR1 on 22q12, can be found in nearly all cases of MLPS.
Regarding synovial sarcomas, a t(X;18) translocation is used to directly assist differentiating synovial sarcoma from other STS (20) . The translocation fuses SYT gene from chromosome 18 to either of the two highly homologous genes at Xp11, SSX1 or SSX2, or in less than 1% of SSX4 cases (21) .
These genomic alterations can be detected in patients' specimens with high accuracy by FISH. Fluorescence in situ hybridization (FISH) is one of the most powerful cytogenetic techniques used by biomedical researchers, and is a routine ancillary tool for pathological diagnosis of different subtypes of STS.
Regarding liposarcomas and synovial sarcomas, FISH is commonly used to detectMDM2 amplification and CHOP rearrangement in liposarcomas and SYT rearrangement in synovial sarcomas (18, 22) .
The current study used the FISH technique as an ancillary tool to detect MDM2 amplification and CHOP rearrangement in liposarcomas and SYT rearrangement in synovial sarcomas, aiming at differentiating liposarcoma and synovial sarcoma subtypes from other morphologically similar sarcomas and benign conditions. Also, the study investigated the rate of discordance between pathologic and cytogenetic results, and reclassified sarcomas according to cytogenetic results. Hematoxylin-Eosin (H&E)-stained slides were prepared, their histopathological features were reviewed by an expert pathologist, and the specimens were classified according to the criteria of the WHO classification system (7).
Materials and Methods Specimens
The specimens consisted of four atypical welldifferentiated liposarcomas (WDLS) (14.8%), six myxoidliposarcomas (22.2%), two pleomorphic liposarcomas (7.4%), five unclassified liposarcomas (18.5%), four synovial sarcomas (14.8%), one small round cell synovial sarcoma (3.7%), and five spindle cell tumors in favor of synovial sarcoma (18.5%) (Table1). FISH was performed on inter phase nuclei present on FFPE tissue sections, according to the manufacturer's instructions. Unstained 3-μm parallel sections were placed on electro-statically positively charged slides (Menzel-Gläster, Braunschweig, Germany). One slide of each patient was stained by H&E and the malignant cell areas were marked by an expert pathologist. The MDM2 (12q15) dual-color probe, CHOP (12q13) dual-color, break-apart probe, and SYT (18q11) dual-color, break-apart probe (Cytocell Aquarius, England) were applied on the marked areas of parallel sections where the malignant cells were present. The hybridized slides were reviewed on an Olympus, BX51 microscope (Olympus, Tokyo, Japan) at x100 magnification with immersion oil using a DAPI/Green/Red triple band pass filter set.
The tissue segments were scored through evaluating a minimum of 100 tumor nuclei per sample. The amplification of MDM2 was defined as an MDM2/CEP12 ratio of ≥2 in 100 tumor cells. The results were considered positive for CHOP and SYT when more than 5% of tumor nuclei had evidence of CHOP or SYT rearrangement.
Regardless of histological classification of samples, they were reclassified according to FISH results and compared with each other.
Results
A total of 27 sarcoma tumor specimens, already diagnosed according to histopathological criteria, were analyzed in the current study. They included 17 liposarcomas (63%) and 10 synovial sarcomas (37%). The specimens belonged to 15 males (55.6%) and 12 females (44.4%) with a mean age of 50 years; ranged from 20 to 82. Table 1 summarizes the tumors histological subtypes, size, and site at the time of diagnosis. The mean and median of tumor size were 16.75 cm and 15 cm (1.7 to 40 cm) in liposarcomas and 13.55 cm and 14.75 cm (4 to 22 cm) in synovial sarcomas cases, respectively. Abdomen and retro peritoneum were the commonest sites of liposarcomas (58.8%), while 70% of synovial sarcomas were located around the limbs. After the initial diagnosis and initiation of treatment, the patients with sarcoma were followed-up. The mean of follow-up period of the patients was 32.3 months (2 to 45 months).
FISH was carried out by commercially available probes for MDM2 gene amplification and CHOP rearrangement in liposarcomas, and for SYT rearrangement in synovial sarcomas. The results of FISH were used to reclassify the tumors (Figure 1) . The most common SYT rearrangement is the translocation (X; 18) (p11.2; q11.2), which is a recurrent, non-random abnormality associated with synovial sarcomas and is observed in up to 90% of tumor specimens.
The pathological and FISH results of the patients with liposarcomawere listed in details in Table 2 . In the cases of synovial sarcomas, SYT rearrangement was observed in three cases (30%) based on the results of FISH; therefore, the diagnosis of synovial sarcoma was revised in seven cases (70%) and changed to other types of sarcoma.
During the follow-up, the rate of recurrence was82% in liposarcomas and 60% of the patients with synovial sarcoma.
Regarding liposarcomas, the recurrence rate of WDLPS and DDLPS subtypes were 70% and 85%, respectively.
Discussion
An accurate diagnosis of different types of STS is important not only to differentiate benign from malignant tumors, but also to predict the Although the analysis of histomorphological and immunohistological features is the main procedure for pathological diagnosis of most types of STS, rarity and wide diversity of these malignancies provide specific diagnostic dilemma. Given the tumor-specific genetic alterations elucidated in recent years, molecular analysis has modified the routine diagnostic workup of different types of STS.
Currently, it is estimated that about 30% of sarcomas harbor specific chromosomal abnormalities such as chromosomal translocations and amplifications result in fusion genes; this provides a useful tool for diagnosis and offers novel and potential targets for future therapeutic approaches (23) .
Various molecular genetic abnormalities are detected in 12q in different subtypes of liposarcoma including t(12;16)(q13;p11), or t(12;22)(q13;q12) translocations, which lead to fusion of transcription factor gene CHOP (DDIT3) (a negative regulator of adipocyte differentiation) with TLS (FUS) or EWS genes in at least 95% of MLS cases, as well as amplification of 12q13-15 encompassing MDM2 and CDK4 genes in well-differentiated and dedifferentiated liposarcomas (24) .
A specific t(X;18)(p11.2;q11.2) translocation resulting in fusion of genes between SYT, on chromosome 18, and SSX1, SSX2, or rarely SSX4 on chromosome X is detectable in 90% of synovial sarcomas (25, 26) . The translocation is found both in the spindle and epithelial components of synovial sarcomas, but not in other spindle cell sarcomas.
FISH is an ideal test to detect such chromosomal abnormalities and differentiate liposarcomas from synovial sarcomas. Specific genetic abnormalities of various sarcoma subtypes, including gene translocation and amplification, can be detected with high sensitivity by FISH.
Recent studies showed that FISH is more specific and sensitive than quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC)to detectMDM2 amplification and CHOP rearrangement in liposarcomas and SYT rearrangement in synovial sarcomas (27, 28) . According to their results, FISH can differentiate different subtypes of sarcomas with high accuracy and sensitivity.
The current study employed the FISH technique to reclassify liposarcomas and synovial sarcomas already classified according to histological features. FISH was performed on 17 liposarcoma and 10 synovial sarcoma tumors with commercially available probes for MDM2 amplification and CHOP and SYT rearrangements. FISH results were used to reclassify the sarcoma cases.
According to histopathological findings, the tumors in the liposarcoma group were classified as follows: four WDLPS (23%), six MLPS (35%), and two PLPS (12%), while five tumors (30%) could not be classified according to histopathological features.
Then FISH analysis was performed to determine MDM2 amplification and CHOP rearrangement; therefore, the liposarcoma specimens were reclassified as 41% WLDLP, 53% DDLPS, and 6% MLPS. All the previously unclassified liposarcomas were classified as well with FISH; in details, two PLPS were reclassified as WDLPS, five MLS as three WDLS and two DDLPS, two WDLPS as DDLPS, and five unclassified liposarcomas as four DDLPS and one MLPS.
FISH and histopathological findings were matched in 48.8% for WDLPS, 12% for MLPS, and poorly matched for DDLPS.
According to the histopathological findings, the tumors in the synovial sarcoma group were classified as four synovial sarcomas (40%), one small round cell synovial sarcoma (10%), and five spindle cell tumors in favor of synovial sarcoma (50%); SYT rearrangements were observed in only three specimens (30%) with no SYT rearrangements in seven specimens (70%). Regarding the synovial sarcoma, there was 20% agreement between FISH and histopathological findings.
These results showed that histopathological findings could not provide conclusive results in 70% of synovial sarcomas and in agreement with previous studies, FISH analysis should be mandatory to accurately diagnose synovial sarcoma and apply appropriate clinical management (29) Based on the obtained results of FISH performed to detect MDM2 gene amplification and CHOP gene rearrangement in liposarcomas, and SYT gene rearrangement in synovial sarcomas, this technique confirmed the diagnosis of such tumors. In particular, detection of such genetic abnormalities with FISH provides means to accurately differentiate the subtypes of liposarcoma from synovial sarcoma.
The current study assessed the specimens already diagnosed as liposarcomas or synovial sarcomas, based on conventional histopathologic examination. After the initial diagnosis and initiation of treatment, the patients with sarcoma were followed-up. The current study results showed that patients with liposarcoma and amplification of MDM2had a high rate of recurrence (47%), and patients with CHOP rearrangement had no recurrence after treatment. In patients with synovial sarcoma, recurrence occurred after initial operation in two out of three cases with SYT rearrangement. In agreement with previous studies, the current study results showed that the detection of these abnormalities by FISH, as an alternative diagnostic approach, is important to predict clinical behavior in patients with liposarcoma and synovial sarcoma (18, 30) .
An interesting facet of the current study was that in cases with unclassified liposarcoms without a definitive histological diagnosis, FISH analysis can be used as an ancillary method to accurately diagnose and classify such cases.
In addition to being a diagnostic utility, detection of MDM2 amplification and CHOP rearrangement impact liposarcoma treatments that use selective MDM2 inhibitors and blockers of trans-activating ability of FUS-CHOP fusion protein (31) .
In brief, the current study results indicated that FISH analysis of MDM2 amplification and CHOP rearrangement in liposarcomas and SYT rearrangement in synovial sarcomas, as well as histopathological findings, were helpful to differentiate such sarcoma subtypes.
